Want to see SE:ACARIX full AI Analyst Report?
ACARIX Stock Chart & Stats
kr0.28
>-kr0.01(-3.04%)
At close: 4:00 PM EST
kr0.28
>-kr0.01(-3.04%)
Day’s Range― - ―
52-Week Rangekr0.18 - kr0.34
Previous CloseN/A
Volume265.37K
Average Volume (3M)1.53M
Market Cap
kr241.51M
Enterprise Valuekr279.54M
Total Cash (Recent Filing)kr28.88M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,123,320,200
10 Day Avg. Volume1,802,468
30 Day Avg. Volume1,526,251
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr19.10M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue is expanding despite the company operating from a small base, indicating increasing adoption of its cardiovascular diagnostic offering. If sustained, this growth can improve operating leverage, broaden commercial reach, and provide a foundation for narrowing losses over the next several quarters.
Gross Margin ImprovementThe substantial gross-margin improvement points to better unit economics and a more favorable revenue mix or cost structure. Higher gross profit per sale gives Acarix greater capacity to fund commercialization and absorb operating expenses as revenue scales, supporting potential future profitability.
Debt-Free Balance SheetA debt-free capital structure reduces refinancing exposure, interest-rate sensitivity, and mandatory cash payments. This gives management more flexibility to direct available resources toward product commercialization and operations, although the benefit depends on securing funding while losses continue.
Bears Say
Deep Operating LossesLosses remain exceptionally large relative to revenue, showing that the current cost base is far above the company’s commercial scale. Even with some narrowing versus prior years, this gap makes sustained profitability distant and leaves results highly dependent on substantial revenue growth or cost reduction.
Persistent Negative Cash FlowA continuing cash outflow means operations are not yet self-funding and the company must rely on external capital to sustain activity. Although burn improved versus 2025, negative operating and free cash flow still constrain investment flexibility and increase financing pressure over the medium term.
Capital ErosionOngoing losses are consuming shareholder capital despite the absence of debt, weakening the balance-sheet cushion available to support the business. Continued equity erosion can increase dependence on future financing and may limit strategic flexibility unless operating performance improves materially.
Acarix AB News
ACARIX FAQ
What was Acarix AB’s price range in the past 12 months?
Acarix AB lowest stock price was kr0.18 and its highest was kr0.34 in the past 12 months.
What is Acarix AB’s market cap?
Acarix AB’s market cap is kr241.51M.
When is Acarix AB’s upcoming earnings report date?
Acarix AB’s upcoming earnings report date is Nov 05, 2026 which is in 26 days.
How were Acarix AB’s earnings last quarter?
Acarix AB released its earnings results on Aug 13, 2026. The company reported -kr0.008 earnings per share for the quarter.
Is Acarix AB overvalued?
According to Wall Street analysts Acarix AB’s price is currently Overvalued.
Does Acarix AB pay dividends?
Acarix AB does not currently pay dividends.
What is Acarix AB’s EPS estimate?
Acarix AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acarix AB have?
Acarix AB has 1,123,320,200 shares outstanding.
What happened to Acarix AB’s price movement after its last earnings report?
Acarix AB reported an EPS of -kr0.008 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acarix AB?
Currently, no hedge funds are holding shares in SE:ACARIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acarix AB
Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADScor System, an exceptionally sensitive, non-invasive analytical device designed for the detection of coronary artery disease. Founded in 2009, Acarix AB (publ) maintains its headquarters in Malmö, Sweden.
Technical Analysis
Senzime AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Scandinavian Real Heart AB
―
Mentice AB
―